PTC Therapeutics Inc (NAS:PTCT)
$ 36.53 3.23 (9.7%) Market Cap: 2.80 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

PTC Therapeutics Inc Translarna Deep Dive Transcript

Dec 15, 2020 / 05:00PM GMT
Release Date Price: $66.37 (+0.55%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the PTC Therapeutics Translarna Deep Dive. (Operator Instructions) I would now like to hand the conference over to your speaker today, PTC, CEO, Stu Peltz. Please go ahead, sir.

Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director

Thank you for joining our Deep Dive series. Today, we're going to focus on Translarna ahead of the dystrophin data readout in the first quarter 2021. We're going to be talking about the totality of evidence to support treatment with a disease-modifying therapy and the regulatory cap and its commercialization. We're planning to hold -- continue to hold a series of Deep Dives in 2021, including one on Huntington's disease ahead of the healthy volunteers data in the first half of 2021 to help you understand what to expect. So I will not be making forward-looking statements. So please look at the SEC documents.

Let's go to Slide 3. PTC has been the pioneer in discovering, developing and commercializing DMD therapies throughout the world.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot